Perfusion Extracorporeal Technology SRL
Perfusion Extracorporeal Technology reported total assets of 32,779 € at the end of the 2025 financial year (annual accounts filed with the NBB on 11 Jun 2026).
The score of Perfusion Extracorporeal Technology shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -8 % Total assets +75 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Perfusion Extracorporeal Technology's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Jun 2026
- Year ended 31 Dec 2024filed on 20 Aug 2025
- Year ended 31 Dec 2023filed on 24 Jul 2024
- Year ended 31 Dec 2022filed on 29 Aug 2023
Perfusion Extracorporeal Technology's financial analysis
- Solvency26.7%sector median: 47.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Perfusion Extracorporeal Technology
1 active director(s) in the register.
Perfusion Extracorporeal Technology's shareholders and holdings →Perfusion Extracorporeal Technology's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0784.827.493
- VAT number
- BE0784827493
- Peppol
- Registered · 0208:0784827493 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 14 Apr 2022
- Registered office
- 5030 Gembloux
- Latest accounts
- 2025 · filed on 11 Jun 2026
- Activity
- Other business support service activities n.e.c. (NACE 82990)
Perfusion Extracorporeal Technology (SRL) has been based in Gembloux since 2022, active in: other business support service activities n.e.c.. For 2025, it reports a net loss of 6,541 € and equity of 8,736 €; its revenue is not published. Its solvency stands at 26.7%, below the median of its sector (47.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Perfusion Extracorporeal Technology
Companies in the same business, of comparable size and area, outside its group.
- Dame au LIT SAD Nursing and midwifery activities Momignies · balance sheet 28,454 €
- Thuisverpleging Peel Nursing and midwifery activities Nieuwpoort · balance sheet 37,084 €
- Pvdk-Care Nursing and midwifery activities Oostkamp · balance sheet 37,933 €
- De Blauwe Lotus Nursing and midwifery activities Herselt · balance sheet 47,932 €
- SOSoins Nursing and midwifery activities Verviers · balance sheet 51,457 €
- Christiaens Lotte Nursing and midwifery activities Waregem · balance sheet 52,009 €
- Elaba Nursing and midwifery activities Ghent · balance sheet 52,631 €
- Caubergs Chris Nursing and midwifery activities Bree · balance sheet 24,638 €
Frequently asked questions about Perfusion Extracorporeal Technology
What is the revenue of Perfusion Extracorporeal Technology?
Perfusion Extracorporeal Technology files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Perfusion Extracorporeal Technology?
In Belgium, the VAT number is the company number prefixed with BE: BE0784827493 for Perfusion Extracorporeal Technology, if the company is VAT-registered. Its company number (CBE) is 0784.827.493.
Where is the registered office of Perfusion Extracorporeal Technology?
According to the CBE register, the registered office of Perfusion Extracorporeal Technology is in 5030 Gembloux.
What is the equity of Perfusion Extracorporeal Technology?
At the close of the 2025 financial year, the equity of Perfusion Extracorporeal Technology amounts to 8,736 €, a solvency of 26.7% of total assets.
Who manages Perfusion Extracorporeal Technology?
The register lists 1 active mandates at Perfusion Extracorporeal Technology. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Perfusion Extracorporeal Technology
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →